JP2004502642A - カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 - Google Patents

カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 Download PDF

Info

Publication number
JP2004502642A
JP2004502642A JP2001558420A JP2001558420A JP2004502642A JP 2004502642 A JP2004502642 A JP 2004502642A JP 2001558420 A JP2001558420 A JP 2001558420A JP 2001558420 A JP2001558420 A JP 2001558420A JP 2004502642 A JP2004502642 A JP 2004502642A
Authority
JP
Japan
Prior art keywords
ethyl
alkyl
methyl
morpholinyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001558420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004502642A5 (enExample
Inventor
カテリナ・レフセリス
ルーリン・ジャオ
チェン・バン−チ
ピーター・キーナー
ウ・ホン
チェンナギリ・アール・パンディット
スティーブン・ローブルスキー
ピン・チェン
ジョン・ハインズ・ジュニア
マリンダ・ロングファー
デレク・ジェイ・ノリス
スティーブン・スパーゲル
ジョン・トカースキー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2004502642A publication Critical patent/JP2004502642A/ja
Publication of JP2004502642A5 publication Critical patent/JP2004502642A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
JP2001558420A 2000-02-11 2001-02-08 カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 Pending JP2004502642A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18181800P 2000-02-11 2000-02-11
PCT/US2001/004131 WO2001058869A2 (en) 2000-02-11 2001-02-08 Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases

Publications (2)

Publication Number Publication Date
JP2004502642A true JP2004502642A (ja) 2004-01-29
JP2004502642A5 JP2004502642A5 (enExample) 2008-03-13

Family

ID=22665935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001558420A Pending JP2004502642A (ja) 2000-02-11 2001-02-08 カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用

Country Status (8)

Country Link
US (1) US6653304B2 (enExample)
EP (1) EP1254115A2 (enExample)
JP (1) JP2004502642A (enExample)
AR (1) AR027406A1 (enExample)
AU (1) AU2001234958A1 (enExample)
CA (1) CA2399791A1 (enExample)
PE (1) PE20020746A1 (enExample)
WO (1) WO2001058869A2 (enExample)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005035993A (ja) * 2003-06-26 2005-02-10 Takeda Chem Ind Ltd カンナビノイド受容体調節剤
WO2006011670A1 (ja) * 2004-07-28 2006-02-02 Takeda Pharmaceutical Company Limited ピロロ［２，３－ｃ］ピリジン化合物、その製造方法および用途
JP2006520795A (ja) * 2003-03-20 2006-09-14 シェーリング　コーポレイション カンナビノイドレセプターリガンド
JP2007523150A (ja) * 2004-02-20 2007-08-16 ユーシーエル・バイオメディカ・ピーエルシー 調節物質
JP2007526281A (ja) * 2004-03-05 2007-09-13 ナームローゼ・フエンノートチヤツプ・オルガノン カンナビノイドｃｂ１受容体のアゴニストとしての、（インドール−３−イル）−複素環誘導体
JP2007530590A (ja) * 2004-03-25 2007-11-01 メモリー・ファーマシューティカルズ・コーポレイション インダゾール、ベンゾチアゾール、ベンゾイソチアゾール、ベンズイソキサゾール、ならびにそれらの調製および使用
WO2008029825A1 (en) * 2006-09-05 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Imidazole derivative
JP2008509202A (ja) * 2004-08-09 2008-03-27 サノフイ−アベンテイス ピロール誘導体、その調製及びその治療上の使用
JP2008524336A (ja) * 2004-12-21 2008-07-10 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしての３−シクロアルキルカルボニルインドール類
JP2008535829A (ja) * 2005-03-31 2008-09-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ テトラヒドロチオピラノピラゾールカンナビノイドモジュレーター
JP2008545739A (ja) * 2005-06-02 2008-12-18 グレンマーク・ファーマシューティカルズ・エスエー 新規なカンナビノイド受容体リガンド、それらを含む薬剤組成物、およびそれらの調製方法
JP2010535816A (ja) * 2007-08-10 2010-11-25 ハー・ルンドベック・アクチエゼルスカベット ヘテロアリールアミド類似体
JP2011506583A (ja) * 2007-12-18 2011-03-03 サノフイ−アベンテイス アゼチジン誘導体、それらの調製、およびそれらの治療における適用
JP2011513226A (ja) * 2008-02-21 2011-04-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するアミン化合物及びエーテル化合物
JP2011515432A (ja) * 2008-03-25 2011-05-19 アフェクティス ファーマシューティカルズ アーゲー 新規ｐ２ｘ７ｒ拮抗薬及びその使用法
JP2014515001A (ja) * 2011-04-20 2014-06-26 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環誘導体

Families Citing this family (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057106A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US6943266B1 (en) 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
JP2003511469A (ja) 1999-10-18 2003-03-25 ユニバーシティ オブ コネチカット 抹消カンナビノイド受容体（ｃｂ２）選択的配位子
US7329651B2 (en) 2001-01-26 2008-02-12 University Of Connecticut Cannabimimetic ligands
ATE478670T1 (de) 2001-01-29 2010-09-15 Univ Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
CA2452881C (en) * 2001-07-13 2012-03-06 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
AU2002331766A1 (en) * 2001-08-31 2003-03-18 University Of Connecticut Novel pyrazole analogs acting on cannabinoid receptors
CA2464333C (en) * 2001-10-26 2011-07-26 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
US20040259936A1 (en) * 2001-12-07 2004-12-23 Nagarkatti Leonard C Treatment of neoplasia
EP1487436A4 (en) 2002-03-08 2009-06-03 Signal Pharm Inc POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
DE60334787D1 (de) 2002-03-12 2010-12-16 Merck Sharp & Dohme Substituierte amide
AU2003220222A1 (en) 2002-03-13 2003-09-29 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
FR2838438A1 (fr) * 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
EP1509250B1 (en) 2002-06-06 2008-05-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods compositions and articles of manufacture for modulating bone growth
TW200402417A (en) 2002-06-21 2004-02-16 Akzo Nobel Nv 1-[(Indol-3-yl)carbonyl]piperazine derivatives
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
HRP20050044A2 (en) 2002-07-29 2005-10-31 F. Hoffmann - La Roche Ag Novel benzodioxoles
WO2004017922A2 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
HRP20050053A2 (en) * 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
EE05516B1 (et) * 2002-09-25 2012-02-15 Memory@Pharmaceuticals@Corporation Indasoolid bensotiasoolid ja bensoisotiasoolid nende valmistamine ning kasutamine
EP1556373A1 (en) * 2002-10-18 2005-07-27 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
FR2847899B1 (fr) * 2002-11-29 2006-04-28 Sanofi Synthelabo Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique
KR100761562B1 (ko) * 2002-12-02 2007-10-04 에프. 호프만-라 로슈 아게 부신피질 자극 호르몬 방출 인자 길항제로서의 인다졸 유도체
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
EP1583762B1 (en) 2003-01-02 2008-07-09 F. Hoffmann-La Roche Ag Pyrrolyl-thiazoles and their use as cb 1 receptor inverse agonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
KR20050096956A (ko) 2003-02-07 2005-10-06 다이이찌 세이야꾸 가부시기가이샤 피라졸 유도체
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
SE0300705D0 (sv) * 2003-03-14 2003-03-14 Biolipox Ab New compounds
SE0300908D0 (sv) * 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
BRPI0410289A (pt) * 2003-05-07 2006-05-16 Pfizer Prod Inc ligantes do receptor de canabinóides e suas utilizações
CN1809552A (zh) * 2003-05-20 2006-07-26 田纳西大学研究基金会 大麻素衍生物、其制备方法和用途
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
EP1498098B1 (en) 2003-07-14 2006-05-03 3M Espe Ag Adhesive composition with decreased polarity upon polymerization
BRPI0412259B1 (pt) 2003-07-22 2019-08-20 Astex Therapeutics Limited Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica
US20050026983A1 (en) * 2003-07-30 2005-02-03 Pfizer Inc Imidazole compounds and uses thereof
MXPA06001660A (es) * 2003-08-14 2006-04-28 Hoffmann La Roche Moduladores gabanergicos.
EP1670787B1 (en) 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
AR045651A1 (es) * 2003-09-19 2005-11-02 Solvay Pharm Bv Derivados de tiazol como moduladores del receptor de cannabinoide
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
US7151097B2 (en) 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
DE602004005893T2 (de) 2003-12-17 2007-09-06 N.V. Organon Trizyklische 1-((3-indol-3-yl)-carbonyl)-piperazin-derivate als cannabinoid-cb1-rezeptoragonisten
JP4705587B2 (ja) * 2003-12-17 2011-06-22 ナームローゼ・フエンノートチヤツプ・オルガノン カンナビノイドｃｂ１受容体アゴニストとしての三環式１−［（３−インドール−３−イル）カルボニル］ピペラジン誘導体
DE602004006166T2 (de) 2003-12-19 2008-01-10 Bristol-Myers Squibb Co. Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
SG149830A1 (en) 2003-12-22 2009-02-27 Memory Pharm Corp Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2- benzisothiazoles, and preparation and uses thereof
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
ES2244314B1 (es) * 2004-02-17 2007-02-01 Laboratorios Del Dr. Esteve, S.A. Compuestos azetidinicos sustituidos, su preparacion y su aplicacion como medicamentos.
AU2005214130B2 (en) * 2004-02-20 2008-03-06 Astrazeneca Ab 3-substituted 1,5-diphenylpyrazole derivatives useful as CB1 modulators
US7452997B2 (en) * 2004-03-24 2008-11-18 Janssen Pharmaceutica, N.V. Tetrahydro-indazole cannabinoid modulators
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
ATE487716T1 (de) * 2004-04-22 2010-11-15 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzisoxazole, 1,2- benzoisothiazole, deren herstellung und verwendungen
RU2386633C2 (ru) 2004-05-07 2010-04-20 Мемори Фармасьютиклз Корпорейшн 1h-индазолы, бензотиазолы, 1, 2-бензоизоксазолы, 1, 2-бензоизотиазолы и хромоны и их получение и применения
BRPI0510679A (pt) 2004-05-10 2007-12-26 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização desses compostos
ES2317244T3 (es) 2004-06-09 2009-04-16 Glaxo Group Limited Derivados de pirrolopiridina.
JP2008509138A (ja) 2004-08-03 2008-03-27 ワイス 心臓血管疾患の治療に有用なインダゾール類
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
EP1794130A1 (en) * 2004-09-20 2007-06-13 Biolipox AB Pyrazole compounds useful in the treatment of inflammation
EP1794145A1 (en) * 2004-09-20 2007-06-13 Biolipox AB Pyrazole compounds useful in the treatment of inflammation
US20070260056A1 (en) * 2004-09-27 2007-11-08 Brandt Thomas A Process for Preparing Bicyclic Pyrazolyl
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
EP2286838A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
SE0402763D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Nitro indazole derivatives
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
PL1828179T3 (pl) * 2004-12-22 2010-08-31 Memory Pharm Corp Ligandy dla receptorów nikotynowych alfa-7 przeciwko chorobom związanym z OUN
JP2008525404A (ja) * 2004-12-23 2008-07-17 アストラゼネカ アクチボラグ 治療剤
WO2006076569A2 (en) * 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
AU2006207325B2 (en) 2005-01-21 2012-08-16 Astex Therapeutics Limited Pharmaceutical compounds
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
WO2006077424A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
CA2601777A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US8937184B2 (en) 2005-02-16 2015-01-20 Abbvie B.V. 1H-imidazole derivatives as cannabinoid CB2 receptor modulators
BRPI0607439A2 (pt) * 2005-02-16 2010-04-06 Solvay Pharm Bv compostos, composição farmacêutica, método de preparação de composições farmacêuticas, e, uso de um composto
TW200700387A (en) * 2005-03-21 2007-01-01 Akzo Nobel Nv 1-benzylindole-2-carboxamide derivatives
WO2006101434A1 (en) * 2005-03-22 2006-09-28 Astrazeneca Ab NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
ES2574014T3 (es) 2005-05-30 2016-06-14 Msd K.K. Derivado de piperidina novedoso
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
GB0514738D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
GB0516379D0 (en) * 2005-08-09 2005-09-14 Glaxo Group Ltd Compounds
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
CA2617649A1 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
BRPI0614904A2 (pt) * 2005-08-12 2012-12-25 Astrazeneca Ab processo para a preparaÇço de uma dispersço estÁvel de partÍculas submÍcron amorfas sàlidas em um meio aquoso, dispersço de partÍculas submÍcron amorfas, e , composiÇço farmacÊutica
CA2619770A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
US7763732B2 (en) 2005-08-24 2010-07-27 N.V. Organon Indole derivatives
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
US20070117857A1 (en) * 2005-09-23 2007-05-24 Fina Liotta Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB2431105A (en) * 2005-10-12 2007-04-18 Gw Pharma Ltd Cannabinoids for the treatment of pulmonary disorders
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
WO2007051982A1 (en) * 2005-10-31 2007-05-10 Biolipox Ab Triazole compounds as lipoxygenase inhibitors
EP1943225A1 (en) * 2005-11-01 2008-07-16 Biolipox AB Pyrazoles useful in the treatment of inflammation
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
EP1953165B1 (en) 2005-11-10 2012-02-01 Msd K.K. Aza-substituted spiro derivative
US20070213359A1 (en) * 2005-12-30 2007-09-13 Acadia Pharmaceuticals Inc. Bicyclic-nitrogen compounds as modulators of ghrelin receptor and uses thereof
JP5159630B2 (ja) 2006-09-13 2013-03-06 協和発酵キリン株式会社 縮環複素環誘導体
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
JPWO2008038692A1 (ja) 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
CA2669675A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. Combination of er.alpha.+ ligands and histone deacetylase inhibitors for the treatment of cancer
WO2008075019A1 (en) 2006-12-18 2008-06-26 7Tm Pharma A/S Modulators of cb1 receptors
US20090325936A1 (en) * 2006-12-20 2009-12-31 Bilodeau Mark T Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
TW200848039A (en) * 2007-02-09 2008-12-16 Astrazeneca Ab Pharmaceutical compositions
TW200848417A (en) 2007-02-22 2008-12-16 Organon Nv Indole derivatives
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
US7781650B2 (en) * 2007-04-30 2010-08-24 Monsanto Technology Llc Plants and seeds of corn variety CV202909
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009015180A2 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
MX2010001566A (es) * 2007-08-06 2010-03-15 Dainippon Sumitomo Pharma Co Derivado de aminopirazolamida.
US20120004222A1 (en) * 2007-08-21 2012-01-05 Zhicai Wu Cb2 receptor ligands for the treatment of pain
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
WO2009089482A1 (en) 2008-01-11 2009-07-16 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
WO2009106980A2 (en) * 2008-02-29 2009-09-03 Pfizer Inc. Indazole derivatives
KR20100126706A (ko) * 2008-02-29 2010-12-02 화이자 인코포레이티드 인다졸 유도체
US20110015181A1 (en) 2008-03-06 2011-01-20 Makoto Ando Alkylaminopyridine derivative
US8815892B2 (en) 2008-03-25 2014-08-26 Affectis Pharmaceuticals Ag P2X7R antagonists and their use
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
US9486441B2 (en) 2008-04-21 2016-11-08 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2009154132A1 (ja) 2008-06-19 2009-12-23 萬有製薬株式会社 スピロジアミン-ジアリールケトオキシム誘導体
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009308980B2 (en) 2008-10-30 2013-02-28 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US8637501B2 (en) 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
US8575186B2 (en) * 2009-10-05 2013-11-05 Albany Molecular Research, Inc. Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
CN103402996B (zh) * 2011-01-04 2015-02-11 诺瓦提斯公司 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
WO2012099952A2 (en) 2011-01-19 2012-07-26 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-ht6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
EP2675459A4 (en) 2011-02-18 2014-08-06 Medivation Technologies Inc COMPOUNDS AND METHOD FOR THE TREATMENT OF DIABETES
KR20150075120A (ko) 2011-02-25 2015-07-02 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
CN103906733A (zh) 2011-06-24 2014-07-02 安姆根有限公司 Trpm8拮抗剂及其在治疗中的用途
WO2012177896A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
EP2847164A4 (en) * 2012-05-11 2015-09-23 Univ Utah Res Found COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND RELATED METHODS
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
RU2520967C1 (ru) * 2013-02-08 2014-06-27 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) СИММЕТРИЧНЫЕ ДИИМИНЫ НА ОСНОВЕ КАМФОРЫ - ИНГИБИТОРЫ РЕПРОДУКЦИИ ВИРУСА ГРИППА (ШТАММ A/California/07/09 (H1N1)pdm09)
EP2958562B1 (en) 2013-02-22 2025-09-10 Merck Sharp & Dohme LLC Antidiabetic bicyclic compounds
MX363727B (es) * 2013-03-07 2019-04-01 Hoffmann La Roche Nuevos derivados de pirazol.
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
HK1220696A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 鸟苷酸环化酶激动剂及其用途
RS57461B1 (sr) 2013-05-02 2018-09-28 Hoffmann La Roche Derivati purina kao agonisti cb2 receptora
EP2991988B1 (en) 2013-05-02 2017-05-31 F. Hoffmann-La Roche AG Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
LT3041843T (lt) 2013-09-06 2019-03-12 F. Hoffmann-La Roche Ag Triazol[4,5-d]pirimidino dariniai kaip cb2 receptorių antagonistai
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US20170157135A1 (en) * 2013-11-25 2017-06-08 Novogen Limited Functionalised and substituted indoles as anti-cancer agents
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
WO2017040963A1 (en) 2015-09-03 2017-03-09 Forma Therapeutics, Inc. [6,6] fused bicyclic hdac8 inhibitors
NZ740587A (en) 2015-09-10 2019-07-26 Suven Life Sciences Ltd Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
CA3010615C (en) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
US10323042B2 (en) 2016-02-23 2019-06-18 Pfizer Inc. 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
AR109950A1 (es) 2016-10-14 2019-02-06 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
CN108794379A (zh) * 2017-04-26 2018-11-13 华东师范大学 1h-吲哚-2-甲酰胺衍生物及其制备方法和应用
SI3652178T1 (sl) * 2017-07-14 2024-05-31 F. Hoffmann-La Roche Ag Biciklične ketonske spojine in načini njihove uporabe
CN111278809B (zh) 2017-10-31 2024-06-25 豪夫迈·罗氏有限公司 二环砜类和亚砜类、以及其使用方法
BR112021001608A2 (pt) 2018-09-10 2021-04-27 Kaken Pharmaceutical Co., Ltd. derivado de amida heteroaromático inovador e medicamento contendo o mesmo
CN109020860B (zh) * 2018-09-25 2021-06-22 宝鸡文理学院 一种2-芳基-3-酯基多取代吡咯类化合物及其合成精制方法
IL283182B2 (en) 2018-11-20 2025-10-01 Tes Pharma S R L Alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase inhibitors
CN113302193A (zh) 2019-01-11 2021-08-24 豪夫迈·罗氏有限公司 双环吡咯并三唑酮化合物及其使用方法
EP3924058B1 (en) 2019-02-13 2026-01-07 Merck Sharp & Dohme LLC 5-alkyl pyrrolidine orexin receptor agonists
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
US12312332B2 (en) 2019-08-08 2025-05-27 Merck Sharp & Dohme Llc Heteroaryl pyrrolidine and piperidine orexin receptor agonists
US20230067205A1 (en) * 2020-07-29 2023-03-02 Medterra Pharma Llc Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders
KR20230053639A (ko) 2020-08-18 2023-04-21 머크 샤프 앤드 돔 엘엘씨 비시클로헵탄 피롤리딘 오렉신 수용체 효능제
CN119330867B (zh) * 2024-09-03 2025-12-02 常州大学 一种吡咯酰胺类衍生物及其制备方法和作为β2-肾上腺素受体别构拮抗剂的应用

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306323A2 (en) * 1987-09-03 1989-03-08 Glaxo Group Limited Lactam derivatives
EP0353983A2 (en) * 1988-08-02 1990-02-07 Glaxo Group Limited Lactam derivatives
EP0394989A2 (en) * 1989-04-28 1990-10-31 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, process for preparation thereof and pharmaceutical composition comprising the same
EP0428434A2 (fr) * 1989-11-06 1991-05-22 Sanofi Composés aromatiques aminés et leurs énantiomères, procédé pour leur préparation et compositions pharmaceutiques les contenant
JPH03161470A (ja) * 1989-11-17 1991-07-11 Nisshin Flour Milling Co Ltd インドール誘導体
EP0445781A1 (en) * 1990-03-08 1991-09-11 Sterling Winthrop Inc. 3-Arylcarbonyl-1-aminoalkyl-1H-indole containing antiglaucoma compositions
WO1994020126A1 (en) * 1993-03-03 1994-09-15 Fujisawa Pharmaceutical Co., Ltd. Use of peptides for the manufacture of a medicament
WO1994022821A1 (en) * 1993-04-05 1994-10-13 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives as testosterone 5 alpha-reductase inhibitors
WO1995000536A1 (en) * 1993-06-22 1995-01-05 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds
WO1995022524A1 (en) * 1994-02-22 1995-08-24 Merrell Pharmaceuticals Inc. Novel indole derivatives useful to treat estrogen-related neoplasms and disorders
WO1996011929A1 (en) * 1994-10-12 1996-04-25 Smithkline Beecham Plc Biheteroaryl-carbonyl and carboxamide derivatives with 5ht 2c/2b antagonists activity
WO1996025397A1 (en) * 1995-02-15 1996-08-22 Merck Frosst Canada Inc. Indole derivatives with affinity for the cannabinoid receptor
WO1996033196A1 (en) * 1995-04-19 1996-10-24 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
WO1997000860A1 (fr) * 1995-06-21 1997-01-09 Sanofi Composes agonistes du recepteur cb¿2?
EP0774460A1 (en) * 1994-03-30 1997-05-21 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compound and use thereof as medicine
JPH09136889A (ja) * 1987-09-03 1997-05-27 Glaxo Group Ltd ５‐ｈｔ３レセプターにおいて５‐ｈｔの作用に拮抗するラクタム誘導体を含む医薬組成物
EP0790254A1 (fr) * 1996-02-16 1997-08-20 Adir Et Compagnie Pseudopeptides dérivés de neurokinines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO1998028292A1 (en) * 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
WO1999024460A2 (en) * 1997-11-05 1999-05-20 Novartis Ag Dipeptide nitriles
WO1999025686A1 (en) * 1997-11-18 1999-05-27 Teijin Limited Cyclic amine derivatives and their use as drugs

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5632549A (en) 1979-08-27 1981-04-02 Toyo Ink Mfg Co Ltd Pigment composition
US4581354A (en) 1984-08-06 1986-04-08 Sterling Drug Inc. 3-arylcarbonyl- and 3-cycloalkylcarbonyl-1-aminoalkyl-1H-indoles, compositions and use
US5013732A (en) 1984-08-06 1991-05-07 Sterling Drug Inc. 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indoles
US4748247A (en) * 1986-10-21 1988-05-31 American Home Products Corporation 2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists
PT95899A (pt) 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
IE68593B1 (en) 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
US5102889B1 (en) * 1990-09-27 1993-05-11 2-(4-piperidinyl)-1h-pyrido(4,3-b)indol-1-ones and related compounds
US5189041A (en) * 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
PL175347B1 (pl) 1992-04-03 1998-12-31 Upjohn Co Trójpierścieniowe heterocykliczne aminy aktywne farmaceutycznie
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
EP0716077A1 (de) 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
NZ318228A (en) 1995-09-01 1999-07-29 Lilly Co Eli Indolyl neuropeptide y receptor antagonists
CA2245586A1 (en) 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
WO1998031227A1 (en) 1997-01-21 1998-07-23 Smithkline Beecham Corporation Novel cannabinoid receptor modulators
WO1998041519A1 (en) 1997-03-18 1998-09-24 Smithkline Beecham Corporation Novel cannabinoid receptor agonists
JP2002523448A (ja) 1998-08-28 2002-07-30 サイオス インコーポレイテッド ｐ３８−αキナーゼのインヒビター

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09136889A (ja) * 1987-09-03 1997-05-27 Glaxo Group Ltd ５‐ｈｔ３レセプターにおいて５‐ｈｔの作用に拮抗するラクタム誘導体を含む医薬組成物
EP0306323A2 (en) * 1987-09-03 1989-03-08 Glaxo Group Limited Lactam derivatives
EP0353983A2 (en) * 1988-08-02 1990-02-07 Glaxo Group Limited Lactam derivatives
JPH02160786A (ja) * 1988-08-02 1990-06-20 Glaxo Group Ltd ラクタム誘導体
EP0394989A2 (en) * 1989-04-28 1990-10-31 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, process for preparation thereof and pharmaceutical composition comprising the same
EP0428434A2 (fr) * 1989-11-06 1991-05-22 Sanofi Composés aromatiques aminés et leurs énantiomères, procédé pour leur préparation et compositions pharmaceutiques les contenant
JPH03161470A (ja) * 1989-11-17 1991-07-11 Nisshin Flour Milling Co Ltd インドール誘導体
EP0445781A1 (en) * 1990-03-08 1991-09-11 Sterling Winthrop Inc. 3-Arylcarbonyl-1-aminoalkyl-1H-indole containing antiglaucoma compositions
WO1994020126A1 (en) * 1993-03-03 1994-09-15 Fujisawa Pharmaceutical Co., Ltd. Use of peptides for the manufacture of a medicament
WO1994022821A1 (en) * 1993-04-05 1994-10-13 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives as testosterone 5 alpha-reductase inhibitors
WO1995000536A1 (en) * 1993-06-22 1995-01-05 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds
WO1995022524A1 (en) * 1994-02-22 1995-08-24 Merrell Pharmaceuticals Inc. Novel indole derivatives useful to treat estrogen-related neoplasms and disorders
EP0774460A1 (en) * 1994-03-30 1997-05-21 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compound and use thereof as medicine
WO1996011929A1 (en) * 1994-10-12 1996-04-25 Smithkline Beecham Plc Biheteroaryl-carbonyl and carboxamide derivatives with 5ht 2c/2b antagonists activity
WO1996025397A1 (en) * 1995-02-15 1996-08-22 Merck Frosst Canada Inc. Indole derivatives with affinity for the cannabinoid receptor
WO1996033196A1 (en) * 1995-04-19 1996-10-24 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
WO1997000860A1 (fr) * 1995-06-21 1997-01-09 Sanofi Composes agonistes du recepteur cb¿2?
EP0790254A1 (fr) * 1996-02-16 1997-08-20 Adir Et Compagnie Pseudopeptides dérivés de neurokinines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO1998028292A1 (en) * 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
WO1999024460A2 (en) * 1997-11-05 1999-05-20 Novartis Ag Dipeptide nitriles
WO1999025686A1 (en) * 1997-11-18 1999-05-27 Teijin Limited Cyclic amine derivatives and their use as drugs

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520795A (ja) * 2003-03-20 2006-09-14 シェーリング　コーポレイション カンナビノイドレセプターリガンド
JP2007211017A (ja) * 2003-03-20 2007-08-23 Schering Plough Corp カンナビノイドレセプターリガンド
JP2005035993A (ja) * 2003-06-26 2005-02-10 Takeda Chem Ind Ltd カンナビノイド受容体調節剤
JP2007523150A (ja) * 2004-02-20 2007-08-16 ユーシーエル・バイオメディカ・ピーエルシー 調節物質
JP2007526281A (ja) * 2004-03-05 2007-09-13 ナームローゼ・フエンノートチヤツプ・オルガノン カンナビノイドｃｂ１受容体のアゴニストとしての、（インドール−３−イル）−複素環誘導体
JP2007530590A (ja) * 2004-03-25 2007-11-01 メモリー・ファーマシューティカルズ・コーポレイション インダゾール、ベンゾチアゾール、ベンゾイソチアゾール、ベンズイソキサゾール、ならびにそれらの調製および使用
JP2011252002A (ja) * 2004-03-25 2011-12-15 Memory Pharmaceuticals Corp インダゾール、ベンゾチアゾール、ベンゾイソチアゾール、ベンズイソキサゾール、ならびにそれらの調製および使用
WO2006011670A1 (ja) * 2004-07-28 2006-02-02 Takeda Pharmaceutical Company Limited ピロロ［２，３－ｃ］ピリジン化合物、その製造方法および用途
JPWO2006011670A1 (ja) * 2004-07-28 2008-05-01 武田薬品工業株式会社 ピロロ［２，３−ｃ］ピリジン化合物、その製造方法および用途
JP2008509202A (ja) * 2004-08-09 2008-03-27 サノフイ−アベンテイス ピロール誘導体、その調製及びその治療上の使用
JP2008524336A (ja) * 2004-12-21 2008-07-10 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしての３−シクロアルキルカルボニルインドール類
JP4922946B2 (ja) * 2004-12-21 2012-04-25 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしての３−シクロアルキルカルボニルインドール類
JP2008535829A (ja) * 2005-03-31 2008-09-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ テトラヒドロチオピラノピラゾールカンナビノイドモジュレーター
JP2008545739A (ja) * 2005-06-02 2008-12-18 グレンマーク・ファーマシューティカルズ・エスエー 新規なカンナビノイド受容体リガンド、それらを含む薬剤組成物、およびそれらの調製方法
JP2009203238A (ja) * 2006-09-05 2009-09-10 Kyowa Hakko Kirin Co Ltd イミダゾール誘導体
WO2008029825A1 (en) * 2006-09-05 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Imidazole derivative
JP2010535816A (ja) * 2007-08-10 2010-11-25 ハー・ルンドベック・アクチエゼルスカベット ヘテロアリールアミド類似体
JP2011506583A (ja) * 2007-12-18 2011-03-03 サノフイ−アベンテイス アゼチジン誘導体、それらの調製、およびそれらの治療における適用
JP2011513226A (ja) * 2008-02-21 2011-04-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するアミン化合物及びエーテル化合物
JP2011515432A (ja) * 2008-03-25 2011-05-19 アフェクティス ファーマシューティカルズ アーゲー 新規ｐ２ｘ７ｒ拮抗薬及びその使用法
JP2014515001A (ja) * 2011-04-20 2014-06-26 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環誘導体
US9340500B2 (en) 2011-04-20 2016-05-17 Shionogi & Co., Ltd. Aromatic heterocyclic derivative having TRPV4-inhibiting activity

Also Published As

Publication number Publication date
AU2001234958A1 (en) 2001-08-20
PE20020746A1 (es) 2002-08-17
CA2399791A1 (en) 2001-08-16
WO2001058869A3 (en) 2002-01-24
US20020119972A1 (en) 2002-08-29
WO2001058869A2 (en) 2001-08-16
AR027406A1 (es) 2003-03-26
EP1254115A2 (en) 2002-11-06
WO2001058869B1 (en) 2002-02-21
US6653304B2 (en) 2003-11-25

Similar Documents

Publication Publication Date Title
JP2004502642A (ja) カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
AU2019240616B2 (en) N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
RU2271361C2 (ru) Амидные производные карбоновой кислоты, способ их получения и фармацевтические композиции на их основе
ES2283609T3 (es) Compuestos.
JP6346862B2 (ja) オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン
JP4211394B2 (ja) プロパン−１，３−ジオン誘導体
JP3416069B2 (ja) デルタオピオイドアゴニストとしての化合物
AU2003284984B2 (en) Gamma-aminoamide modulators of chemokine receptor activity
JP2005511475A6 (ja) メラノコルチン受容体のモジュレーターとして有用な化合物及びそれを含む製薬組成物
JP2005511475A (ja) メラノコルチン受容体のモジュレーターとして有用な化合物及びそれを含む製薬組成物
JP7434281B2 (ja) Ｐａｄ酵素のベンズイミダゾール阻害剤
JP2002524512A (ja) ｃＧＭＰホスホジエステラーゼの縮合ピリジン阻害剤
HRP20010854A2 (en) INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
EP2297112A1 (en) Pyrazole compounds as ccr1 antagonists
JPWO2002002533A1 (ja) プロパン−１，３−ジオン誘導体
JP2010508358A (ja) グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用
KR20070116633A (ko) 피지디2 길항제 활성을 갖는 1-아세틱 애시드-인돌 유도체
KR20190141180A (ko) 선택적 hdac6 저해제
JP2021505684A (ja) ヒストンデアセチラーゼ６阻害剤としての１，２，４−オキサジアゾール誘導体
TW202017916A (zh) 新穎緩激肽ｂ２受體拮抗劑及其用途
BG106638A (bg) Нови циклопропани като cgrp-антагонисти, лекарствени средства, които ги съдържат и метод за получаването им
SK105294A3 (en) Indole derivatives, method of their preparation, intermediates of this process, pharmaceutical agents containing these derivatives and use of these derivatives
JP2009179616A (ja) ３−ナフチルピラゾール化合物
US7235662B2 (en) Modulators of the glucocorticoid receptor and method
WO2004020584A2 (en) Antagonists of chemokine receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110426

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111011